• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    The Bull Case For Legend Biotech (LEGN) Could Change Following Its CAR-T Scale-Up And In Vivo Pivot

    Simply Wall St·09/01/2026 22:22:12
    Listen to the news
    • Legend Biotech recently highlighted its position as a leading standalone cell therapy company, underscoring the commercial rollout of its autologous CAR-T therapy CARVYKTI for multiple myeloma and its expanding manufacturing network in the US and Europe, alongside interim CEO Alan Bash’s participation in a past Morgan Stanley Global Healthcare Conference fireside chat.
    • An important angle for investors is Legend’s push into next-generation in vivo CAR-T approaches, which could eventually simplify treatment logistics by generating CAR-T cells directly inside patients after a single infusion.
    • Next, we’ll examine how Legend’s manufacturing scale-up to serve thousands of CAR-T patients annually may influence its broader investment narrative.

    Outshine the giants: these 19 early-stage AI stocks could fund your retirement.

    Legend Biotech Investment Narrative Recap

    To own Legend Biotech, you need to believe that a focused cell therapy company built around CARVYKTI and follow‑on programs can justify its heavy investment in manufacturing and R&D. The Morgan Stanley fireside chat and management’s emphasis on scale and in vivo CAR‑T do not materially change the near term focus on CARVYKTI execution or the key risk of dependence on a single commercial asset and a relatively new leadership team.

    Among recent developments, the June 2026 first‑in‑human data for LB2501, Legend’s in vivo CD19/CD20 CAR‑T, look especially relevant here. While the Morgan Stanley event highlights Legend’s positioning, LB2501’s early efficacy and safety readout is more directly tied to the long term catalyst of reducing manufacturing bottlenecks and product concentration risk if it eventually progresses toward commercialization.

    Yet, despite this progress, investors should be aware that concentration in CARVYKTI still leaves Legend exposed if...

    Read the full narrative on Legend Biotech (it's free!)

    Legend Biotech's narrative projects $2.2 billion revenue and $464.7 million earnings by 2029. This requires 20.2% yearly revenue growth and about a $556 million earnings increase from -$91.5 million today.

    Uncover how Legend Biotech's forecasts yield a $49.25 fair value, a 133% upside to its current price.

    Exploring Other Perspectives

    LEGN 1-Year Stock Price Chart
    LEGN 1-Year Stock Price Chart

    The most cautious analysts were already modeling revenue of about US$2.0 billion and earnings of roughly US$105 million by 2029, so this new focus on scaling and in vivo CAR T could either challenge their concerns about pricing and competition or reinforce them, depending on how you view the trade off between growth potential and the risks around reimbursement and concentration.

    Explore 5 other fair value estimates on Legend Biotech - why the stock might be worth over 6x more than the current price!

    Form Your Own Verdict

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    Want Some Alternatives?

    These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.